Gene study spots clues to heart risk for statin patients

(Vanderbilt University Medical Center) A Vanderbilt-led research team has discovered genetic variations that increase the risk of heart attack even when patients are receiving a statin drug like Lipitor or Crestor to lower their blood cholesterol.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

ConclusionsPatients undergoing a coronary revascularization procedure who received moderate-intensity statins plus ezetimibe showed similar rates of major adverse cardiovascular events as patients who received high-intensity statins.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
This study population consists of 100 patients with stable CAD who will undergo PCI and have high low-density lipoprotein cholesterol levels despite administration of maximum tolerated dose of statins for at least 2 weeks. Eligible patients are randomized in a 1:1 ratio to receive either evolocumab 140 mg every 2 weeks in addition to standard of care treatment or standard of care treatment only for 2-6 weeks before PCI. The primary endpoint is IMR after PCI. The EVOCATION trial will evaluate whether pretreatment with evolocumab reduces periprocedural microvascular damage in patients with stable CAD undergoing PCI.PMID:3451...
Source: Journal of Cardiology - Category: Cardiology Authors: Source Type: research
In this study, mature DCs (mDCs), generated from the GM-CSF and IL-4 induced bone marrow cells, were intravenously injected into wild-type mice. Three days later, assays showed that the mDCs were indeed able to return to the thymus. Homing DCs have been mainly reported to deplete thymocytes and induce tolerance. However, medullary TECs (mTECs) play a crucial role in inducing immune tolerance. Thus, we evaluated whether the mDCs homing into the thymus led to TECs depletion. We cocultured mDCs with mTEC1 cells and found that the mDCs induced the apoptosis and inhibited the proliferation of mTEC1 cells. These effects were onl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Eur J Vasc Endovasc Surg. 2021 Sep 7:S1078-5884(21)00537-2. doi: 10.1016/j.ejvs.2021.06.031. Online ahead of print.ABSTRACTOBJECTIVE: The aims of this study were to assess the incidence of major vascular events (MVE) and peripheral vascular events (PVE) in people with a small asymptomatic abdominal aortic aneurysm (AAA) and model the theoretical benefits and costs of an intensified low density lipoprotein cholesterol (LDL-C) lowering programme.METHODS: A total of 583 participants with AAAs measuring 30 - 54 mm were included in this study. The control of LDL-C and prescription of lipid lowering drugs were assessed by dividi...
Source: PubMed: Eur J Vasc Endovasc ... - Category: Surgery Authors: Source Type: research
IT IS estimated there are more than eight million people using statins in the UK. The drug is taken primarily to help manage high cholesterol levels, thereby warding off all associated complications; notably stroke and heart attack. Another side effect, however, could arise following use of the drug.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
AbstractPatients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convert...
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
STATINS effectively lower cholesterol and protect against heart attack and stroke. They are one of the most widely prescribed drugs, but as with most drugs, there are potential side effects to note including a change in your hair.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
HIGH cholesterol is the prerequisite to heart disease, a heart attack, or stroke - three life-threatening conditions. A free NHS health check - available from the age of 40 - can indicate where you're heading in life.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Doctors say inclisiran will prevent tens of thousands of deaths from heart attack and strokePatients in England are to start receiving a “gamechanger” drug that doctors say will protect tens of thousands of lives by cutting the number of people who have a heart attack or stroke.The treatment, inclisiran, works by boosting the liver ’s ability to reduce the body’s level of “bad” cholesterol, even in those who have already tried using statins.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Drugs Health Heart attack Stroke UK news NHS National Institute for Health and Care Excellence Source Type: news
AbstractCardiovascular disease (CVD) is one of the leading causes of death worldwide. CVD includes coronary artery diseases such as angina, myocardial infarction, and stroke. “Lipid hypothesis” which is also known as the cholesterol hypothesis proposes the linkage of plasma cholesterol level with the risk of developing CVD. Conventional management involves the use of statins to reduce the serum cholesterol levels as means for CVD prevention or treatment. The regulati on of serum cholesterol levels can potentially be regulated with biological interventions like monoclonal antibodies. Phage display is a powerful ...
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cholesterol | Crestor | Genetics | Heart | Heart Attack | Lipitor | Rosuvastatin | Statin Therapy | Study | Zivast